Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature.

Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S.

J Affect Disord. 2019 Jan 1;242:195-210. doi: 10.1016/j.jad.2018.06.045. Epub 2018 Jun 27.

PMID:
30195173
2.

Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database.

Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, Greenberg PE.

J Clin Psychiatry. 2018 Mar/Apr;79(2). pii: 17m11725. doi: 10.4088/JCP.17m11725.

3.

Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression.

Olfson M, Amos TB, Benson C, McRae J, Marcus SC.

J Manag Care Spec Pharm. 2018 Mar;24(3):226-236. doi: 10.18553/jmcp.2018.24.3.226.

4.

Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.

Edwards SJ, Hamilton V, Nherera L, Trevor N.

Health Technol Assess. 2013 Nov;17(54):1-190. doi: 10.3310/hta17540. Review.

5.

Treatment-resistant depression increases health costs and resource utilization.

Lepine BA, Moreno RA, Campos RN, Couttolenc BF.

Braz J Psychiatry. 2012 Dec;34(4):379-88.

6.

The economic impact of depression: resistance or severity?

Fostick L, Silberman A, Beckman M, Spivak B, Amital D.

Eur Neuropsychopharmacol. 2010 Oct;20(10):671-5. doi: 10.1016/j.euroneuro.2010.06.001. Epub 2010 Jul 10.

PMID:
20624674
7.

The economic burden of treatment-resistant depression.

Olchanski N, McInnis Myers M, Halseth M, Cyr PL, Bockstedt L, Goss TF, Howland RH.

Clin Ther. 2013 Apr;35(4):512-22. doi: 10.1016/j.clinthera.2012.09.001. Epub 2013 Mar 13.

PMID:
23490291
8.

Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database.

Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N.

PLoS One. 2013 Oct 18;8(10):e76882. doi: 10.1371/journal.pone.0076882. eCollection 2013.

9.

Medicaid spending burden among beneficiaries with treatment-resistant depression.

Pilon D, Sheehan JJ, Szukis H, Singer D, Jacques P, Lejeune D, Lefebvre P, Greenberg PE.

J Comp Eff Res. 2019 Apr;8(6):381-392. doi: 10.2217/cer-2018-0140. Epub 2019 Feb 8.

10.

Identification of a claims data "signature" and economic consequences for treatment-resistant depression.

Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ.

J Clin Psychiatry. 2002 Aug;63(8):717-26.

PMID:
12197453
11.

Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?

Pilon D, Sheehan JJ, Szukis H, Morrison L, Zhdanava M, Lefebvre P, Joshi K.

J Affect Disord. 2019 Aug 1;255:50-59. doi: 10.1016/j.jad.2019.04.100. Epub 2019 May 1.

12.

Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.

Sussman M, O'sullivan AK, Shah A, Olfson M, Menzin J.

J Manag Care Spec Pharm. 2019 Jul;25(7):823-835. doi: 10.18553/jmcp.2019.25.7.823.

13.

Medicare patient experience with vagus nerve stimulation for treatment-resistant depression.

Feldman RL, Dunner DL, Muller JS, Stone DA.

J Med Econ. 2013;16(1):62-74. doi: 10.3111/13696998.2012.724745. Epub 2012 Sep 17.

PMID:
22954061
14.

A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013.

Mrazek DA, Hornberger JC, Altar CA, Degtiar I.

Psychiatr Serv. 2014 Aug 1;65(8):977-87. doi: 10.1176/appi.ps.201300059. Review.

PMID:
24789696
15.

US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study.

Pilon D, Szukis H, Joshi K, Singer D, Sheehan JJ, Wu JW, Lefebvre P, Greenberg P.

Pharmacoecon Open. 2019 Jun 28. doi: 10.1007/s41669-019-0154-z. [Epub ahead of print]

16.

Economic implications of treatment-resistant depression among employees.

Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A.

Pharmacoeconomics. 2004;22(6):363-73.

PMID:
15099122
17.

The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review.

Floyd DN, Langham S, Séverac HC, Levesque BG.

Dig Dis Sci. 2015 Feb;60(2):299-312. doi: 10.1007/s10620-014-3368-z. Epub 2014 Sep 26. Review.

PMID:
25258034
18.

The health-related quality of life burden of co-morbid cardiovascular disease and major depressive disorder in Australia: findings from a population-based, cross-sectional study.

O'Neil A, Stevenson CE, Williams ED, Mortimer D, Oldenburg B, Sanderson K.

Qual Life Res. 2013 Feb;22(1):37-44. doi: 10.1007/s11136-012-0128-4. Epub 2012 Feb 10.

19.

Definition of treatment-resistant depression - Asia Pacific perspectives.

Ng CH, Kato T, Han C, Wang G, Trivedi M, Ramesh V, Shao D, Gala S, Narayanan S, Tan W, Feng Y, Kasper S.

J Affect Disord. 2019 Feb 15;245:626-636. doi: 10.1016/j.jad.2018.11.038. Epub 2018 Nov 5.

20.

Defining treatment-resistant depression: a comprehensive review of the literature.

Trevino K, McClintock SM, McDonald Fischer N, Vora A, Husain MM.

Ann Clin Psychiatry. 2014 Aug;26(3):222-32. Review.

PMID:
25166485

Supplemental Content

Support Center